Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News United Therapeutics Corp UTHR

Healthcare Biotechnology
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended... see more

Recent & Breaking News (NDAQ:UTHR)

10 Hottest Stocks From October 22, 2018

Benzinga.com  October 22, 2018

CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

PR Newswire October 22, 2018

United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

GlobeNewswire October 16, 2018

United Therapeutics Corporation To Host Science Day 2018

PR Newswire September 18, 2018

Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate

PR Newswire September 17, 2018

United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products

GlobeNewswire September 4, 2018

United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

PR Newswire August 30, 2018

United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso

PR Newswire August 8, 2018

United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint

PR Newswire August 8, 2018

United Therapeutics Corporation To Present At 2018 Wedbush PacGrow Healthcare Conference

PR Newswire August 7, 2018

United Therapeutics Corporation Reports Second Quarter 2018 Financial Results

PR Newswire August 1, 2018

SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics

GlobeNewswire July 31, 2018

United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®

PR Newswire July 31, 2018

United Therapeutics Corporation To Report Second Quarter 2018 Financial Results Before The Market Opens On Wednesday, August 1, 2018

PR Newswire July 26, 2018

HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.

GlobeNewswire July 20, 2018

United Therapeutics And XVIVO Perfusion Announce Collaboration To Reduce Organ Shortage Through Expansion Of Organ Evaluation Service

PR Newswire June 12, 2018

SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results

GlobeNewswire May 15, 2018

United Therapeutics Corporation Reports First Quarter 2018 Financial Results

PR Newswire May 2, 2018

Earnings Scheduled For May 2, 2018

Benzinga.com  May 2, 2018

Merger Monday Makes A Return

Benzinga.com  April 30, 2018